TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05042102

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepezil + Cognitive remediation therapy (CRT)
Description: Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepezil + Placebo CRT
Description: Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo medication + Cognitive remediation therapy (CRT)
Description: Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo medication + Placebo CRT
Description: Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
Study: NCT05611814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Targeted anatomical structures are Scalene Muscles (Anterior/Middle/Posterior), Sternocleidomastoid Muscles (SCM), Suboccipital region, Cervical Paraspinal Muscles, Levator Scapulae Muscles, Upper Thoracic Paraspinal Muscles, Upper Trapezius Muscles, Atlanto-occipital (OA), Atlanto-axial (AA), C2-C7 vertebrae, T1-T4 vertebrae, Rib 1 bilaterally. Techniques include Suboccipital Myofascial Release, Soft tissue inhibition, kneading stretching, Facilitated Positional Release, and muscle energy technique.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Targeted anatomical structures are Thoracic Paraspinal Muscles, Lumbar Paraspinal Muscles, Lower Trapezius Muscles, Sacrum, Supraspinatus, T5-T12, and Rib 2-12. Techniques include Soft tissue inhibition, Stretching, Kneading, counterstrain, Facilitated Positional Release, and muscle energy technique.~L1-L5
Study: NCT05701046

Intervention type: PROCEDURE
Intervention: Interbody fusion surgery
Description: Interbody fusion surgery

Intervention type: PROCEDURE
Intervention: Interbody fusion surgery
Description: Interbody fusion surgery
Study: NCT05893472

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of venetoclax and HAA regimen
Description: Using the combination of venetoclax and HAA regimen as induction therapy in young, newly diagnosed adult acute myeloid leukemia patients under the age of 60.
Study: NCT05553418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-clinic wear first
Description: Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home wear first
Description: Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
Study: NCT05883254

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
Description: Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels

Intervention type: DIAGNOSTIC_TEST
Intervention: RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
Description: Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels
Study: NCT05104541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: In addition to standard pharmacological treatment this group would receive diet comprising of 20-25 kcal and 1.2gm protein per kg ideal body weight per day.~The total distribution of the calories would be as 55-60% from carbohydrates, 25% from protein and 20% from fat. The diet would be explained to the patient with the help of individual diet charts.
Study: NCT06174909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide
Description: After completion of canal and shaping ,canal was dried and CH was placed as an intracanal medicament. A total of 100 mg of CH powder was dispensed and mixed with one drop of pro-pylene glycol on a clean and dry glass slab to prepare a thick paste-like consistency. This paste was carried into the canal and access opening was restored temporarily with temporary cement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antibiotic paste
Description: After completion of cleaning and shaping ,canal was dried and tripe antibiotic was placed as intracanal medicament.It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle. This paste was placed gently compacted into the canal and access opening was restored with temporary cement
Study: NCT06487247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEME-Hospice Program
Description: A care delivery program that combines home-based transfusions with routine home hospice care. Transfusions are administered by trained transfusion nurses. Standard hospice care is provided by an interdisciplinary team of non-transfusion nurse case managers, hospice aides, social workers, and chaplains.
Study: NCT04942990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calisthenic exercises
Description: these exercises are a kind of exercise for increasing cardiovascular endurance
Study: NCT05173701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Selected probiotics mixture, in powder form, will be administered once daily for three months in the morning.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo (2,7g maltodextrin) will be administered once daily for three months in the morning.
Study: NCT05622214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Else nutrition formula
Description: Plant based nutrition from almond and buckwheat
Study: NCT05897697

Intervention type: OTHER
Intervention: Interview
Description: Structured interview
Study: NCT05856565

Intervention type: OTHER
Intervention: Photo
Description: Photography intake

Intervention type: OTHER
Intervention: Photo
Description: Photography intake
Study: NCT05058846

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood, tissue, and saliva collection

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood, tissue, and saliva collection

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Undergo MRCP

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Undergo MRCP

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05905068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN0191 INJECTION
Description: a sterile solution in each bottle for subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN0191 INJECTION
Description: a sterile solution in each bottle for subcutaneous (SC) injection
Study: NCT04075240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG and acetylsalicylic acid 81 mg
Description: Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG and acetylsalicylic acid 81 mg
Description: Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid 81 mg
Description: Starting post op, aspirin for 9 days for TKA and 30 days for THA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid 81 mg
Description: Starting post op, aspirin for 9 days for TKA and 30 days for THA
Study: NCT05058846

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: Undergo endoscopic ultrasound
Study: NCT04849806

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessments of the sympathetic nerve activity axis
Description: For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessments of the sympathetic nerve activity axis
Description: For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA severity
Description: OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
Study: NCT05058846

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: Undergo endoscopic ultrasound

Intervention type: OTHER
Intervention: Questionnaires
Description: Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
Study: NCT05529004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Capsule pregapalin
Description: oral cap of pregapalin has been administration to patient before surgery to prvent PONV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laparoscope device
Description: general anesthesia with complete relaxation under laparoscopic cholecystectomy
Study: NCT04849806

Intervention type: DIAGNOSTIC_TEST
Intervention: OSA severity
Description: OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
Study: NCT05258539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire.
Study: NCT05117177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inupadenant
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inupadenant
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inupadenant
Description: Oral administration
Study: NCT04849806

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of PH and right HF severity
Description: (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of PH and right HF severity
Description: (defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
Study: NCT06481085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 50 mg
Description: HDM1002 tablets, 50 mg once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 100 mg
Description: HDM1002 tablets, 100 mg once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 200 mg
Description: HDM1002 tablets, 200 mg once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 400 mg
Description: HDM1002 tablets, 400 mg once daily, 12 weeks
Study: NCT04849806

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive lung function and inspiratory muscle function testing.
Description: Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive lung function and inspiratory muscle function testing.
Description: Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
Study: NCT05905068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RN0191 INJECTION
Description: a sterile solution in each bottle for subcutaneous (SC) injection
Study: NCT04849806

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of systemic inflammation
Description: Based on blood samples taken.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of systemic inflammation
Description: Based on blood samples taken.
Study: NCT06325956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Take metformin for six months.
Study: NCT04741828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vi-DT Typhoid Conjugate Vaccine
Description: Typhoid Conjugate Vaccine
Study: NCT06421389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
Study: NCT06481085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM1002 200 mg BID
Description: HDM1002 tablets, 200 mg twice daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided
Study: NCT05004129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: All subjects will receive weight-adjusted 1000 mg tideglusib following a titration period of 2 weeks at a weight-adjusted dose of 400 mg and 2 weeks at a weight-adjusted dose of 600 mg tideglusib.
Study: NCT04787562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 250mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Drug: XNW4107 100mg IV over 60 minutes as a single dose~Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose
Study: NCT06460649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation techniques
Description: Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation techniques
Description: Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benson relaxation techniques
Description: Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
Study: NCT06139419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: definitive radiotherapy
Description: Participants were treated with definitive thoracic radiotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: definitive radiotherapy
Description: Participants were treated with definitive thoracic radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemo-immunotherapy
Description: All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.

Intervention type: DRUG
Group type: OTHER
Intervention: induction chemo-immunotherapy
Description: All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).

Intervention type: DRUG
Group type: OTHER
Intervention: concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotheapy consolidation
Description: Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Immunotheapy consolidation
Description: Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months.
Study: NCT04789174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solriamfetol
Description: Solriamfetol 75 mg/d Solriamfetol 150 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04912765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Dendritic Cell Vaccine
Description: 10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
Study: NCT06041438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: itraconazole
Study: NCT04108858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study: NCT05211726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Added Sugar Diet
Description: Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Added Sugar Diet
Description: Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Study: NCT05534230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution
Description: Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.